PA-PMI
The world’s most brilliant strategies are only as strong as the teams behind them, Project Management Institute (PMI)’s latest Pulse of the Profession® In-Depth report claims. According to the report, due to unprecedented workplace evolution and complexity, more than half of all organizations are already reorganizing their activities around projects – requiring employers to reimagine how talent is deployed to solve problems and get work done. The study, Tomorrow’s Teams Today , explores how the future of work has led to the future of teams, and how agile, change-ready teams—led by strong power skills including collaboration, empathy and innovation—will thrive in and drive The Project Economy.
The introduction of automation, demand for flexible working conditions, and desire for agility has shifted individual roles and responsibilities within organizations. The report identified three core principles to prioritize when building ready-for-anything project teams:
- Make agility part of the team DNA: As roles and responsibilities are reimagined, teams that adopt an all-for-one mentality will be best prepared to adjust on the fly.
- Look beyond technical prowess: Bring together talent who have the new power skills: empathy, collaboration and communication.
- The customer is king: Forward-thinking teams make user feedback the core of planning and execution to generate meaningful solutions with long-term benefits.
“The rapid evolution of the workplace has led to many companies organizing task flow through projects, leading to teams who thrive on change and embrace a more agile workstyle,” said Michael DePrisco, vice president, global experience & solutions at PMI. “We see this as a positive step and expect teams that excel in a changing environment will better navigate priorities from multidisciplinary stakeholders.”
According to the report, organizations need teams that can gracefully pivot amid changes to a scope or customer demands, and when embracing new technology. More than 50 percent of project professionals say they’ve worked on at least one team that uses disruptive technology like artificial intelligence (AI) or machine learning, and half of those respondents expect to work on more AI teams over the next year.
As tasks increasingly become automated, executives are starting to look beyond the technical realm when evaluating talent. The Tomorrow’s Teams Today report identified five essential team skills valued the most:
- Collaborative Leadership
- Empathy for the Voice of the Customer
- Risk Management
- Innovative Mindset
- Methodology or Framework Governance
With recruiting practices relying more on soft skills than ever before, organizations are transforming to agile working models to incorporate new talent with modern skills. Nearly 1 in 4 projects completed over the past year used agile and half of project management offices expect this number to increase in the next 5 years. The 2020 Pulse of the Profession also found that 42 percent of projects in the past year were characterized as having “high complexity,” which average 24 core team members compared to 8 members for “low complexity” projects.
“The must-have skills for projects have evolved well beyond the usual technical skills that have been used for generations,” DePrisco added. “This will be especially apparent as more large-scale projects are introduced to improve world infrastructure, enhance cybersecurity measures and more.”
Read more about the 2020 Pulse of the Profession In-Depth Report: Tomorrow’s Teams Today .
About Project Management Institute (PMI)
Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Through global advocacy, collaboration, education and research, we work to prepare more than three million professionals around the world for The Project Economy: the coming economy in which work, and individuals, are organized around projects, products, programs and value streams. Now 50 years in the making, we work in nearly every country around the world to advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org , www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005641/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
